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CovalentThe tetrodecamycins are a group of secondary metabolites that are characterized by the presence of a
tetronate ring in their structure. Originally discovered for their antibiotic activity against
Photobacterium damselae ssp. piscicida, the causative agent of pseudotuberculosis in fish, this family of
molecules has also been shown to have potent antibiotic activity against methicillin-resistant
Staphylococcus aureus. Due to their small size and highly cyclized nature, they represent an unusual mem-
ber of the much larger group of bioactive molecules called the tetronates. Herein, we review what is
known about the mechanism of action of these molecules and also present a hypothesis for their biosyn-
thesis. A deeper understanding of the tetrodecamycins will provide a more holistic view of the tetronate-
family, provide new chemical probes of bacterial biology, and may provide therapeutic lead molecules.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since the early 1940s, more than 107 bacteria have been
screened for their ability to produce bioactive molecules. This
has resulted in the identification of more than 2000 antibiotics that
are divided into a variety of classes.1,2 While there are numerous
mechanisms by which bioactive molecules can be assembled, a
particularly common mechanism is the polyketide synthases
(PKS). These biosynthetic machines iteratively link carbon atoms
together, using acetyl-CoA, malonyl-CoA, methylmalonyl-CoA and
other related precursors to form linear carbon chains. Subsequent
cyclization and tailoring of the linear molecules generates
compounds with a magnificent diversity of structures and wide-
ranging bioactivities.3,4 Examples that illustrate this diversity
include actinorhodin (antibacterial),5 tetracycline (antibacterial),6
FK506 (immunosuppressant),7 doxorubicin (chemotherapeutic),8
amphotericin B (antifungal),9 erythromycin (antibacterial),10
lovastatin (anti-cholesterol drug),11 as well as the numerous
tetronate-family molecules which are the subject of this review.
The bioactivities of the tetronate family range from antiviral12 to
antibacterial13 to antitumor.14
The tetronates are characterized by a unique, five-membered
lactone ring called a tetronate ring (Fig. 1A). This family wasrecently divided into three subfamilies: the linear tetronates, the
spirotetronates, and the miscellaneous tetronates.15 The linear
tetronates are epitomized by molecules such as agglomerin A,16
acaterin,17 didehydro-acaterin,18 RK-682,12 pesthetoxin,19 and
tetronomycin20 (Fig. 1B). These molecules are characterized by a
tetronate ring modified with a carbon chain attached at either
the C-3 or C-5 position. The attached carbon chains, synthesized
as either a fatty acid or a polyketide, may be saturated or unsatu-
rated and may include additional small rings (e.g., tetronomycin).
The spirotetronate molecules, themselves the topic of dedicated
reviews,21 are characterized by a spirotetronate ring system (in
which a six-membered ring and the tetronate ring are linked to
form a spirane) and a macrocyclic ring. This group is further
divided into three groups on the basis of the size of their macro-
cyclic ring: the small spirotetronates have a macrocyclic ring of
11 carbons (e.g., maklamicin,22 nomimicin,23 abyssomicin C13);
the medium spirotetronates have a macrocyclic ring of 13 carbons
(e.g. chlorothricin,24 kijanimicin,25 tetrocarcin,26 decatromicin B27);
and the large spirotetronates have more than 13 carbons in their
macrocyclic ring (e.g., quartromicin,28 versipelostatin,29 tetronoth-
iodin30) (Fig. 1B).
Finally, the last group of tetronate molecules is the miscella-
neous tetronates. As the name suggests, these are tetronate mole-
cules which do not fit into any of the above categories. This group
includes members like the artapetalins (excluded from the linear
tetronate group because they are alkylated, not acylated, at the
C-3 position),31 picrodendrin B (which possess an unusual
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Figure 1. The tetronate family of molecules all possess a tetronate ring. (A) The tetronate ring is a 5-membered lactone ring. Modifications to the ring are commonly found at
R1 and R2. (B) The tetronate family can be divided into three general subfamilies: the linear tetronates, the spirotetronates, and the miscellaneous tetronates. Representing the
linear tetronates are agglomerin A, acaterin, tetronomycin, didehydro-acaterin, pesthetoxin, and RK-682. Representing the small spirotetronates are maklamicin, nomimicin,
and abyssomicin C. Representing the medium spirotetronates are chlorothricin, tetrocarcin A, kijanimicin, and decatromicin B. Representing the large spirotetronates are
quartromicin D3, tetronothiodin, and versipelostatin. Representing the miscellaneous tetronates are picrodendrin B and artapetalin A.
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group (TDM-group) molecules: tetrodecamycin (TDM), dihydro-
tetrodecamycin (dhTDM), and 13-deoxytetrodecamycin (13-dTDM)
(Fig. 2).33,342. History of the tetrodecamycins
TDMwas first reported in 1994 in a brief letter followed later by
a description of the producing strain, fermentation, isolation, and
the structural elucidation of TDM and a related compound, dhTDM
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Figure 2. The tetrodecamycins are a small group of related molecules which are
classified as miscellaneous tetronates.
T. Gverzdys et al. / Bioorg. Med. Chem. 24 (2016) 6269–6275 6271(Fig. 2).33,35,36 The organism that produces both of these molecules,
Streptomyces nashvillensis MJ885-mF8, was isolated from a soil
sample collected in Suginami-ku, Tokyo, Japan. Studies into this
wild-isolate streptomycete were commenced with the observation
that it produced anti-bacterial activity against Photobacterium
damselae ssp. piscicida (formerly described as Pasteurella
piscicida37). P. damselae ssp. piscicida is the causative agent of pseu-
dotuberculosis in fish (also called pasteurellosis or photobacterio-
sis). Indeed, the name piscicida is derived from the Latin words
‘‘fish” (piscus) and ‘‘to kill” (-cidus).38 The disease presents as a
bacterial septicemia followed by the development of tubercles on
internal organs that can ultimately prove fatal.39 At the time,
cultured yellowtail (Seriola quinqueradiata, also called Japanese
amberjack) accounted for 56% of the farmed fish produced in Japan
and losses due to pseudotuberculosis had significant economic
impact on the industry.40 Antibiotics were in use to treat this
infection but, mirroring the same problem observed in human
health, the widespread use of antibiotics was accompanied by
the reciprocal development of antibiotic resistance.41 This led to
the need for new antibiotics.
TDM and dhTDM were isolated from ethyl acetate extracts of S.
nashvillensis in liquid culture. The structures of TDM, dhTDM, and
14-O-acyltetrodecamycin (a semi-synthetic derivative of TDM)
were determined by NMR (Fig. 2). The structure revealed a tetra-
cyclic molecule with a 6,6,7,5-membered ring system: the pair of
six-membered rings are arranged in a decalin system, the seven-
membered ring is a heterocycle containing an oxygen, and the
five-membered ring is a tetronate ring.33,36
One of the characteristic features of TDM is the presence of an
exo-methylene attached to the tetronate ring at position C-5
(Fig. 2). In contrast, dhTDM possesses a methyl group at this same
position. The presence of this exo-methylene is interesting due to
its infrequent occurrence in the other tetronate ring-containing
compounds (Fig. 1) and because it also forms a potential Michael
acceptor that could influence the molecule’s bioactivity (discussed
further below). Bioassays performed with TDM confirmed that it
had strong antibiotic activity against P. damselae ssp. piscicida
(1.56–6.25 lg mL1, 4.67–18.7 lM) as well as antibiotic activity
against a number of strains of Staphylococcus aureus, methicillin-
resistant S. aureus (MRSA), Micrococcus luteus, and Bacillus subtilis
(6.25–12.5 lg mL1, 18.7–37.4 lM). Interestingly, despite the
potent activity of TDM against P. damselae ssp. piscicida (a Gram-
negative organism), it showed no antibiotic activity against other
Gram-negative organisms tested. dhTDM showed almost noantibiotic activity against any of the organisms tested, including
P. damselae ssp. piscicida. TDM has been reported to have no toxi-
city in mice up to 100 mg kg1 when introduced by intraperitoneal
injection, though due to a lack of materials and methods pertaining
to this result, this information should be considered with care. In
vitro cytotoxicity studies were never conducted.33,36
A follow-up study by the same group attempted to improve the
bioactivity of TDM by making modifications to the 14-OH position
and the exo-methylene.42 A patent was filed for the molecule and
its derivatives (patent number JPH0892256), though there is no
evidence that the molecule was ever used in the clinic or for aqua-
culture. Following these studies, no further work on the molecule
was reported until 2000, at which time a number of groups
attempted to synthesize the molecule. An initial retrosynthetic
analysis of tetrodecamycin suggested that this structure could be
synthesized from a decalin derivative and a tetronic acid
derivative, inspiring the first efforts toward the synthesis of
tetrodecamycin.43 This strategy made two features of the molecule
important targets in these early synthetic studies: the asymmetric
synthesis of the novel seven-membered ring core,43–45 and the
synthesis of the decalin portion of the molecule.46–48 These efforts
culminated with the successful total synthesis of tetrodecamycin
2006 through a pinacol cyclization mechanism.49
In 2015, we published the first report of a new, naturally-
occurring tetrodecamycin since the initial 1995 report of TDM
and dhTDM. The producer strain, Streptomyces species strain
WAC04657, was identified from a panel of wild-isolate Strepto-
myces because of its ability to inhibit the growth of MRSA. The
molecule responsible for the activity, 13-dTDM, differs from TDM
by the lack of a hydroxyl group at C-13 on the decalin ring
(Fig. 2). The change in the decalin ring results in marginally greater
activity against Gram-positive organisms (from 1 to 8 lg mL1,
3.14 to 25.2 lM) when compared to TDM.34
Given the anti-MRSA activity, the presence of a Michael accep-
tor, and the lack of knowledge about the TDM-group molecules, we
went on to identify the biosynthetic gene cluster (the ted genes)
that encodes 13-dTDM.50 We identified the same cluster in three
other strains of Streptomyces. Surprisingly, none of these organisms
produced 13-dTDM, though two of them, Streptomyces atrooli-
vaceus ATCC 19725 and Streptomyces globisporus ssp. globisporus
NRRL B-2293, produced TDM and dhTDM. For reasons unknown,
the third organism, Streptomyces sp. LaPpAH-202, did not produce
any TDM-group molecules. A surprising discovery that came out of
this work was the identification of a novel molecule, W5.9, also
produced by the ted genes in S. str. WAC04657 but lacking the
canonical tetronate ring expected from TDM-group molecules. At
the current time, we believe this molecule may be a shunt product
produced by the cluster.
3. Mechanism of action
At present, the mechanism of action and molecular target of the
TDM-group molecules are unknown, although the potentially reac-
tive exo-methylene stands out as a clue. Both TDM and 13-dTDM
possess a Michael acceptor composed of the conjugated system
that extends through C-6/C-1, C-2, C-3, C-4 and C-5 (Fig. 2). Due
to the presence of the electronegative carbonyls at C-6 and C-1,
the exo-methylene at C-5 is expected to act as an electrophile in
a nucleophilic addition reaction (Fig. 3). The only difference
between dhTDM, which has no antibiotic activity, and TDM is the
lack of this exo-methylene. Notably, dhTDM still possesses a
Michael acceptor formed by C-6/C-1, C-2, and C-3. This strongly
suggests that the exo-methylene is important for bioactivity.
Indeed, this idea has been proposed on several occasions based
on similar evidence.42,44 Further, since thiol compounds can be
easily added to the exo-methylene,42 one group has hypothesized
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Figure 3. The proposed mechanism by which the tetrodecamycins could bind
covalently to their target. The conjugated system composed of C-1/C-6, C-2, C-3,
C-4, and C-5 forms a possible Michael acceptor. Due to the presence of the
electronegative carbonyls, C-5 is able to act as an electrophile in a nucleophilic
addition reaction, potentially with a proteinaceous target. This results in the
formation of a covalent bond with the target molecule. ‘‘X” denotes the nucleophile
attached to the target biomolecule.
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with a functional cysteine residue of a target protein.45
There are several synthetic studies that provide further insight
into how TDM might work. In these studies, derivatives orO
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S. aureus FDA209P while compounds 5–8 were measured against S. aureus ATCC 25923.semi-structures of TDM were tested for their bioactivity (Fig. 4).
In one of these papers, the authors reported making modifications
to two different places in the structure of TDM: the 14-OH position
and the exo-methylene.42 To the 14-OH position, various benzene
groups were added as either ethers or esters. These derivatives
exhibited only minor changes to their activity, ranging from a
2-fold decrease to 4-fold increase. The compound that showed
the greatest increase in activity against S. aureus, compound 1,
was modified with a naphthalene moiety (0.78 lg mL1,
1.61 lM). Given the hydrophobic nature of naphthalene, the
modification could cause better targeting of the molecule to the
bacterial membrane, thus suggesting that the target of TDM may
be at this location.
The addition of bromines or thiols to the exo-methylene
(molecules 2–4) reduced the compound’s antibiotic activity
against S. aureus though the results are somewhat contradictory.
While compound 4 lost all activity, compounds 2 and 3 retained
some antimicrobial activity, an observation that is difficult to rec-
tify with the view that the exo-methylene’s reactivity is essential.
Possible explanations include the idea that the exo-methylene
can be restored via a retro-Michael reaction, thus regenerating
the unmodified TDM which subsequently restores the bioactiv-
ity.45 Alternatively, it is possible that some TDM-group molecules
may be able to function through another mechanism independent
of the Michael acceptor. Neither of these ideas have been tested at
this time.
Additional evidence about TDM’s function came from work
involving partial structures of TDM.45 It was shown that molecule
5 had no bioactivity against S. aureus, while one of the synthetic
precursors, molecule 8, did. Therefore, while the exo-methylene
is necessary for antibiotic activity, it is not sufficient. This suggests
that the molecule exerts its activity through a specific bindingO
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which the compound simply reacts covalently with multiple tar-
gets on the cell surface.51,52 Further derivatives of 5, including
molecule 6 (which was active) and molecule 7 (which was not
active), support the idea that the molecule’s overall structure and
chemical properties are important, consistent with a specific
molecular target rather than promiscuous action.
An important question is why TDM showed bioactivity against
the Gram-negative organism P. damselae ssp. piscicida, but not
against Escherichia coli, Klebsiella pneumoniae, or Pseudomonas
aeruginosa.33,35 Interestingly, some TDM-derivatives that showed
increased activity against S. aureus showed no bioactivity against
P. damselae ssp. piscicida (e.g., molecule 1). This and other examples
where there is a lack of concordance between activity against
S. aureus and P. damselae (e.g. molecules 2, 3, and 4) could be
consistent the TDMs having more than one mechanism of action.
While this is rare and, again, untested, there is precedent for this
idea in the case of streptomycin.53
4. Biosynthesis
Careful examination of the ted cluster and comparison to
well-studied tetronate molecules54 has allowed us to propose a
biosynthetic pathway for the TDM-group molecules (Fig. 5). TheFigure 5. Proposed biosynthesis for 13-deoxytetrodecamycin, tetrodecamycin, andcarbon backbone of the TDM-group molecules is produced by a
type I PKS. Bioinformatic analysis of the PKS genes suggests that
the backbone is synthesized by 7 modules (1 loading module and
6 extension modules) and that most of the integrated monomers
are derived from malonyl CoA with the exception of a methyl-
malonyl CoA used by module 5. Release of the backbone from
the final module is expected to be concurrent with formation of
the tetronate ring.50
Detailed studies on tetronate ring formation have been carried
out for tetronomycin,55 RK-682,56 agglomerin,57 and quartro-
micin.58,59 Given that homologues of all the tetronate biosynthesis
proteins have been found in the ted cluster, it is likely that tetro-
nate ring formation follows the same pathway in the TDM-group
molecules. The first step involves taking 1,3-bisphosphoglycerate
from primary metabolism and loading it onto a conserved cysteine
residue of TedF1, an FkbH-family protein. During this step, both
phosphates are removed to yield a glyceryl moiety linked to TedF1.
Next, this glyceryl moiety is transferred to TedF2, a dedicated acyl
carrier protein. TedF5, a FabH-like enzyme, then uses the glyceryl-
S-TedF2 to catalyze the release of the carbon backbone from the
PKS and subsequently generate the immature tetronate ring
(molecule 9). The final step in tetronate ring formation involves
elimination of 5-OH from 9 to form the exo-methylene. This step
involves an acetylation-elimination step in which TedF3, an acetyldihydrotetrodecamycin. Details of the biosynthesis are described in Section 4.
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hydroxyl (molecule 10) followed by elimination of acetic acid from
this position by TedF4, an a/b hydrolase, thus generating the
exo-methylene (molecule 11).
Progressing from the linear PKS backbone of intermediate 11 to
the recognizable tetrodecamycin scaffold would require two
distinct tasks: formation of the decalin ring, and the closure of
the seven-membered heterocycle (Fig. 5). In the literature, an
intramolecular Diels–Alder has been proposed for the formation
of the decalin ring of maklamicin60 and could likewise be respon-
sible for the formation of the decalin rings in other tetronates
including nomimicin, chlorothricin,61 kijanimicin,62 tetrocarcin
A,63 and decatromicin B (Fig. 1B). Following suit, we postulate that
the decalin ring in the TDM natural products could also be formed
by an intramolecular Diels–Alder reaction. In this process, the
C-7/C-8 alkene in intermediate 11 would act as a dienophile in
the cycloaddition with the diene at C-13 to C-16, yielding the dec-
alin ring in intermediate 12. Enzymes known to catalyze
intramolecular Diels–Alder reactions have been identified.64–69
Interestingly, the enzyme TedJ shows homology to previously
identified Diels–Alderases,70 suggesting that this protein may be
responsible for formation of the decalin ring.
Next, the heterocyclic ring central to the tetrodecamycin scaf-
fold would be formed. Based on a similar reaction which has been
suggested for abyssomicin (Fig. 1B),71 we propose that the cycliza-
tion resulting in this heterocyclic ring would proceed through two
steps. First, the alkene present at C-14/C-15 in intermediate 12
would undergo an epoxidation giving intermediate 13. A nucle-
ophilic attack on the epoxide C-15 by the oxygen on C-3 would
result in a seven-membered heterocyclic ring and simultaneously
open the epoxide, which upon protonation, would give a hydroxyl
on C-14. The resulting product, 13-dTDM, could then proceed
through other tailoring steps to give a spectrum of analogues in
the TDM-group including TDM and dhTDM.
In S. str. WAC04657, 13-dTDM appears to be the end-product of
this biosynthetic pathway,34 yet it is a logical next step to add a
hydroxyl to C-13 to generate TDM. Next, reduction of the
exo-methylene to a methyl would generate dhTDM. While our
proposed biosynthesis suggests that dhTDM is the end product, it
brings about an interesting question: why would a biosynthetic
gene cluster capable of making potent antibiotics then convert
the molecules into an inactive form? Attempts to find enzymes
which catalyze the conversion of didehydro-acaterin into acaterin
(Fig. 1B) were unable to find a specific protein responsible for this
activity.72,73 Thus, it is possible that the reduction of TDM’s
exo-methylene into a methyl may be the result of a non-enzymatic
process that generates dhTDM as an unintended byproduct.5. Conclusions
Our intent in this paper has been to review what is known in
the relatively scant literature of the tetrodecamycin family and
to propose some cogent hypotheses for their biosynthesis and
mechanism of action. While there is a great deal left to learn about
this family, their potent action against resistant pathogens such as
MRSA suggests that they merit continued investigation. Identifying
their mechanism of action could lead to new molecular targets for
antimicrobial development.Acknowledgements
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